TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

19 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicPeptide & GLP-1Mental healthLungs & breathingHeart & circulationKidneyBrain & memoryBlood disordersImmune & autoimmuneSkin

18 studies on the map

Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis — Northwestern Memorial Hospital, ChicagoRimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US — MedStar Health: Neurology at McLean, McLeanDalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis — MGH Institute of Health Professions, BostonHome Based Infusions for Ocrelizumab — Amerita, CentennialProphylactic Transfusion In Pregnant in Women With Sickle Cell Disease — Grady Health System, AtlantaProspective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod — University of Colorado Anschutz Medical Campus, AuroraStudy of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis — Johns Hopkins University, BaltimoreA Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache — Maimonides Medical Center, BrooklynGlucose Consumption in MS Using [F-18]FDG-PET — Brigham & Women's Hospital, BostonA Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine — Hope Clinical Research, Canoga ParkSilodosin for Urinary Symptoms in Female Patients With Multiple Sclerosis — Atlantic Health, MorristownEffectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications — Mayo Clinic in Arizona, PhoenixEffectiveness of Nontraditional Hydroxyurea Algorithms: Novel and Clinical Evaluations (ENHANCE) — Cincinnati Children's Hospital Medical Center, CincinnatiClinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease — Emory University, AtlantaOcrelizumab Discontinuation in Relapsing Multiple Sclerosis — Yale School of Medicine, New HavenRollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study — University Of Alabama, BirminghamQudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old — Upsher-Smith Clinical Trial Site #5, BirminghamComparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study — Northern Arizona Healthcare, Flagstaff